September 30th 2024
The event will focus on innovating with cutting-edge technology, featuring the likes of pharmaceutical technology companies revolutionizing the industry.
FDA approves first generic Lexapro to treat depression, anxiety disorder
March 14th 2012Teva/IVAX Pharmaceuticals gained FDA approval for the first generic version of Lexapro (Forest) to treat both depression and generalized anxiety disorder in adults. The company will have 180 days to exclusively sell the product.
FDA approves first cell-based product to treat oral mucogingival conditions in adults
March 9th 2012FDA approved the first cell-based product made from allogeneic human cells and bovine collagen (Gintuit, Organogenesis) for the treatment of oral mucogingival conditions in adults, the agency announced Friday.
Better antibiotic stewardship needed as C. difficile-associated diarrhea surges
March 8th 2012The Centers for Disease Control and Prevention is calling for more appropriate use of antibiotics to combat historically high levels of mortality associated with Clostridium difficile infections in hospitals and other healthcare settings.
Bevacizumab an effective treat-and-extend regimen for AMD
March 8th 2012A treat-and-extend regimen of intravitreal bevacizumab (Avastin, Genentech) produced ?significant visual improvements? for eyes with neovascular age-related macular degeneration, according to an article published in the March issue of the American Journal of Ophthalmology.